These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20163245)

  • 1. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia.
    Weinstein DA; Correia CE; Conlon T; Specht A; Verstegen J; Onclin-Verstegen K; Campbell-Thompson M; Dhaliwal G; Mirian L; Cossette H; Falk DJ; Germain S; Clement N; Porvasnik S; Fiske L; Struck M; Ramirez HE; Jordan J; Andrutis K; Chou JY; Byrne BJ; Mah CS
    Hum Gene Ther; 2010 Jul; 21(7):903-10. PubMed ID: 20163245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
    Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
    Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
    Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors.
    Beaty RM; Jackson M; Peterson D; Bird A; Brown T; Benjamin DK; Juopperi T; Kishnani P; Boney A; Chen YT; Koeberl DD
    Gene Ther; 2002 Aug; 9(15):1015-22. PubMed ID: 12101432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
    Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
    Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
    Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
    Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
    Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
    Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
    Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
    Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.
    Lee YM; Conlon TJ; Specht A; Coleman KE; Brown LM; Estrella AM; Dambska M; Dahlberg KR; Weinstein DA
    J Inherit Metab Dis; 2018 Nov; 41(6):977-984. PubMed ID: 29802554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.
    Koeberl DD
    J Inherit Metab Dis; 2012 Jul; 35(4):671-8. PubMed ID: 22310927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
    Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
    Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant AAV-directed gene therapy for type I glycogen storage diseases.
    Chou JY; Mansfield BC
    Expert Opin Biol Ther; 2011 Aug; 11(8):1011-24. PubMed ID: 21504389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
    Jauze L; Monteillet L; Mithieux G; Rajas F; Ronzitti G
    Hum Gene Ther; 2019 Oct; 30(10):1263-1273. PubMed ID: 31319709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
    Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
    Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
    Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
    J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.